Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Cell Immunol. 2011 Oct 25;272(2):220–229. doi: 10.1016/j.cellimm.2011.10.008

Fig. 7.

Fig. 7

Inhibiting Myd88 function impacts growth and chemokine expression by additional breast cancer models. (A) Three murine mammary carcinoma were treated with 100uM control peptide (CP) or Myd88 inhibitory peptide (MP) for 24 hours and then the cell number was determined using trypan blue staining. (B) After 72 hours of treatment with 100uM CP or MP, mRNA was isolated from the murine mammary carcinomas and QRT-PCR was used to determine CCL2 and CCL5 expression levels using gapdh as the reference gene and CP treated cells as the control. (C) The human breast cancer cell line MDA-MB-231 was treated with 100uM control peptide (CP) or Myd88 inhibitory peptide (MP) for 24–72 hours and then the cell number was determined using trypan blue staining. (D) After 72 hours of treatment with 100uM CP or MP, mRNA was isolated from MDA-MB-231 and QRT-PCR was used to determine CCL2 and CCL5 expression levels using gapdh as the reference gene and CP treated cells as the control. All data represent the average and standard deviation of 3 separate experiments. Where indicated (*) p < 0.05 using Student’s t-Test relative to CP treated cells.